Sutro Biopharma, Inc. (STRO)
NASDAQ: STRO · Real-Time Price · USD
23.48
-0.53 (-2.21%)
Jul 28, 2026, 1:34 PM EDT - Market open
Sutro Biopharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 73.68 | 58.13 | 190.3 | 69.27 | 47.25 | 30.41 |
Short-Term Investments | 128.88 | 83.3 | 126.59 | 306.35 | 287.11 | 167.52 |
Cash & Short-Term Investments | 202.56 | 141.43 | 316.9 | 375.62 | 334.36 | 197.94 |
Cash Growth | -18.64% | -55.37% | -15.63% | 12.34% | 68.92% | -46.23% |
Accounts Receivable | 12.48 | 3.98 | 8.62 | 36.08 | 7.12 | 12.45 |
Other Current Assets | 5.93 | 5.52 | 17.8 | 9.85 | 11.67 | 8.12 |
Total Current Assets | 220.97 | 150.93 | 343.31 | 421.54 | 353.15 | 218.52 |
Net Property, Plant & Equipment | 19.07 | 21.55 | 35.87 | 44.76 | 51.06 | 51.59 |
Long-Term Investments | - | - | - | - | - | 68.78 |
Other Long-Term Assets | 1.95 | 1.35 | 8.03 | 4.44 | 2.73 | 2.53 |
Total Assets | 241.99 | 173.83 | 387.21 | 470.74 | 406.94 | 341.41 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 5.49 | 7.57 | 10.48 | 9.44 | 4.8 | 6.01 |
Accrued Expenses | 48.33 | 49.22 | 44.16 | 53.16 | 27.91 | 19.82 |
Current Portion of Long-Term Debt | - | - | - | 4.06 | 12.5 | 9.38 |
Current Portion of Leases | 7.6 | 7.78 | 7.48 | 6.42 | 4.59 | 1.04 |
Unearned Revenue | 9.4 | 10.56 | 69.78 | 20.67 | 16.76 | 5.5 |
Total Current Liabilities | 70.81 | 75.13 | 131.89 | 93.75 | 66.55 | 41.74 |
Long-Term Debt | - | - | - | - | 3.77 | 15.74 |
Long-Term Leases | 6.03 | 7.89 | 15.67 | 23.15 | 29.57 | 31.22 |
Other Long-Term Liabilities | 232.03 | 223.26 | 195.04 | 204.19 | 90 | 0.15 |
Total Long-Term Liabilities | 238.06 | 231.15 | 210.71 | 227.34 | 123.35 | 47.11 |
Total Liabilities | 308.88 | 306.28 | 342.61 | 321.09 | 189.9 | 88.84 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.02 | 0.01 | 0.01 | 0.06 | 0.06 | 0.05 |
Additional Paid-in Capital | 949.64 | 845.48 | 831.42 | 708.98 | 670.22 | 586.24 |
Accumulated Other Comprehensive Income | -0.1 | 0.02 | 0.04 | 0.02 | -0.62 | -0.31 |
Retained Earnings | -1,016 | -977.96 | -786.87 | -559.41 | -452.62 | -333.41 |
Shareholders' Equity | -66.89 | -132.45 | 44.6 | 149.65 | 217.05 | 252.56 |
Total Liabilities & Equity | 241.99 | 173.83 | 387.21 | 470.74 | 406.94 | 341.41 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 13.63 | 15.67 | 23.15 | 33.64 | 50.43 | 57.37 |
Net Cash (Debt) | 188.93 | 125.75 | 293.74 | 341.98 | 283.93 | 140.56 |
Net Cash Growth | -16.98% | -57.19% | -14.11% | 20.45% | 102.00% | -59.09% |
Net Cash Per Share | 19.50 | 14.80 | 37.97 | 56.84 | 55.96 | 30.48 |
Book Value | -66.89 | -132.45 | 44.6 | 149.65 | 217.05 | 252.56 |
Book Value Per Share | -6.90 | -15.59 | 5.76 | 24.87 | 42.78 | 54.76 |
Tangible Book Value | -66.89 | -132.45 | 44.6 | 149.65 | 217.05 | 252.56 |
Tangible Book Value Per Share | -6.90 | -15.59 | 5.76 | 24.87 | 42.78 | 54.76 |